Synergistic Effects of Gemcitabine and Gefitinib in the Treatment of Head and Neck CarcinomaPatrick Chun, Mukesh K. Nyati|Cancer Research|2006Cited by 78
Evaluation of immune-related response criteria (irRC) in patients (pts) with advanced melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475.F. Stephen Hodi, Jedd D. Wolchok, Jeffrey S. Weber et al.|Journal of Clinical Oncology|2014Cited by 40
Randomized comparison of two doses of the anti-PD-1 monoclonal antibody MK-3475 for ipilimumab-refractory (IPI-R) and IPI-naive (IPI-N) melanoma (MEL).Omid Hamid, Adil Daud, Caroline Robert et al.|Journal of Clinical Oncology|2014Cited by 25
Patterns of response in patients with advanced melanoma treated with Pembrolizumab (MK-3475) and evaluation of immune-related response criteria (irRC)F. Stephen Hodi, Jedd D. Wolchok, Antoni Ribas et al.|Journal for ImmunoTherapy of Cancer|2014Cited by 12
Randomized comparison of two doses of the anti-programmed death-1 monoclonal antibody MK-3475 for ipilimumab (IPI)-refractory and IPI-naive melanomaRichard Kefford, Adil Daud, Omid Hamid et al.|Unknown|2014Cited by 0